Company news

Clinuvel Pharmaceuticals Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

EMA approves year-round SCENESSE treatment

September 22, 2025

SCENESSE efficacy in vitiligo - new cases presented to EADV

September 18, 2025

Investor Presentation

August 27, 2025

CLINUVEL delivers ninth consecutive revenues growth & profit

August 27, 2025

Appendix 4E and Annual Report to Shareholders 2025

August 27, 2025

CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist

August 22, 2025

CLINUVEL preparing upgrade of ADR program, NASDAQ uplist

August 21, 2025

Study confirms NB-UVB needed to activate repigmentation

June 17, 2025

CLINUVEL management update

June 12, 2025

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

May 7, 2025

CUV recruits 200 patients in Phase III vitiligo trial CUV105

May 6, 2025

CLINUVEL renews share buy-back program

March 26, 2025

Positive preliminary results for PRENUMBRA Instant in stroke

March 25, 2025

Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025

March 3, 2025

Half Year Results Announcement

February 27, 2025

Preliminary results from SCENESSE adolescent EPP study

February 9, 2025

Vitiligo - CUV105 Study Update

January 19, 2025

Health Canada validates SCENESSE New Drug Submission

December 22, 2024

Chair's letter to Shareholders

December 4, 2024

SCENESSE dosage expansion under review by EMA

November 19, 2024

CLINUVEL prioritises three strategic programs

November 17, 2024

Managing Director Presentation

October 15, 2024

Canadian New Drug Submission for SCENESSE in EPP filed

September 30, 2024

CLINUVEL delivers increases in annual revenue, profit

August 28, 2024

Appendix 4E and Annual Report to Shareholders 2024

August 28, 2024

Vitiligo and Operational Update

August 20, 2024

Afamelanotide Assists DNA Repair Response Following UVR

July 5, 2024

CLINUVEL extends Managing Director Employment Agreement

June 28, 2024

afamelanotide in fair-skinned Parkinsons patients

June 17, 2024

CLINUVEL initiates on market share buy-back program

March 14, 2024

New case of SCENESSE efficacy in vitiligo presented at AAD

March 10, 2024

SCENESSE provides photoprotection in variegate porphyria

March 3, 2024

CUV Appendix 4D Half Year Report

February 21, 2024

Appendix 4E and Annual Report to Shareholders 2023

August 29, 2023

Quarterly Activities/Appendix 4C Cash Flow Report

January 30, 2023

Quarterly Activities/Appendix 4C Cash Flow Report Re-issued

October 30, 2022

S&P DJI Announces September 2022 Quarterly Rebalance

September 2, 2022

Appendix 4E and Annual Report 2022

August 30, 2022

Positive Final Results in Stroke Study CUV801

May 3, 2022

ACTH Manufacturing Update

March 16, 2022

afamelanotide in Stroke (AIS) - Positive Preliminary Results

March 14, 2022

CLINUVEL Reports December Half Year Operating Results

February 22, 2022

Appendix 4D Half Year Report

February 22, 2022

Response to ASX Price Query

November 7, 2021

CLINUVEL Delivers Record Revenues and Profit

August 26, 2021

Appendix 4E and Preliminary Financial Report

August 26, 2021

Appendix 4C - quarterly

April 29, 2021

Media Release - CLINUVEL expands DNA Repair Program

March 23, 2021

Appendix 4D Half Yearly Report

February 24, 2021

CLINUVEL Strategic Update - Extended

October 29, 2020

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 62 decks. Every deck is listed under its year.